Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, United States.
Front Immunol. 2020 May 13;11:937. doi: 10.3389/fimmu.2020.00937. eCollection 2020.
Dysregulation of osteoclastic differentiation and its activity is a hallmark of various musculoskeletal disease states. In this review, the complex molecular factors underlying osteoclastic differentiation and function are evaluated. The emerging role of KLF2 in regulation of osteoclastic differentiation is examined, specifically in the context of rheumatoid arthritis in which it has been most extensively studied among the musculoskeletal diseases. The therapies that exist to manage diseases associated with osteoclastogenesis are numerous and diverse. They are varied in their mechanisms of action and in the outcomes they produce. For this review, therapies targeting osteoclasts will be emphasized, though it should be noted that many therapies exist which bolster the action of osteoblasts. A new targeted molecular approach is under investigation for the future potential therapeutic development of rheumatoid arthritis.
破骨细胞分化和活性失调是各种肌肉骨骼疾病状态的标志。在这篇综述中,评估了破骨细胞分化和功能的复杂分子因素。特别考察了 KLF2 在调节破骨细胞分化中的新兴作用,在肌肉骨骼疾病中,类风湿关节炎是研究最多的疾病。存在许多针对与破骨细胞生成相关疾病的治疗方法,它们的作用机制和产生的结果各不相同。在这篇综述中,将重点介绍针对破骨细胞的治疗方法,但值得注意的是,有许多治疗方法可以增强成骨细胞的作用。一种新的靶向分子方法正在被研究用于未来类风湿关节炎的潜在治疗开发。